Allogene Therapeutics, Inc.
ALLO
$1.21
-$0.01-0.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 14.72% | 0.34% | 9.58% | 0.10% | -2.09% |
| Total Depreciation and Amortization | 0.23% | -4.14% | 0.81% | -11.99% | 2.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -7.97% | -18.58% | -47.08% | 59.03% | 56.41% |
| Change in Net Operating Assets | 73.04% | -257.38% | 159.36% | 51.71% | -225.42% |
| Cash from Operations | 26.26% | -44.23% | 16.81% | 30.62% | -13.76% |
| Capital Expenditure | 55.56% | 61.48% | 40.09% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 599.27% | -88.63% | 173.04% | -201.27% | 236.99% |
| Cash from Investing | 609.76% | -88.76% | 172.29% | -201.85% | 237.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -85.77% | 85.27% | 745.80% | -99.36% | 6,343.82% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 6.21% | -- | -- | -100.00% | -- |
| Cash from Financing | -63.75% | 143.60% | 745.80% | -99.37% | 6,482.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 130.15% | -236.63% | 120.08% | -199.83% | 472.49% |